Clinical Study to Evaluate the Efficacy of Febuxostat in the Treatment of Conservatively Managed Intracranial Hemorrhage Patients

Summary

To assess the effect of Febuxostat on clinical outcomes and biomarkers of oxidative stress and inflammation in patients with conservatively managed intracranial hemorrhage.

Timeline

Start

2025-11-20

Primary completion

2026-10-30

Completion

2027-01-30

Publications

• Background Bodien YG, Barra A, Temkin NR, Barber J, Foreman B, Vassar M, Robertson C, Taylor SR, Markowitz AJ, Manley GT, Giacino JT, Edlow BL; TRACK-TBI Investigators. Diagnosing Level of Consciousness: The Limits of the Glasgow Coma Scale Total Score. J Neurotrauma. 2021 Dec;38(23):3295-3305. doi: 10.1089/neu.2021.0199.
• Background Bai Y, Shi H, Zhang Y, Zhang C, Wu B, Wu X, Fang Z, Wang Q, Sima X, Zhang T. Febuxostat attenuates secondary brain injury caused by cerebral hemorrhage through inhibiting inflammatory pathways. Iran J Basic Med Sci. 2024;27(6):740-746. doi: 10.22038/IJBMS.2024.74655.16212.

Drugs

Indications